Fintel reports that on March 25, 2025, Raymond James upgraded their outlook for HealthEquity (NasdaqGS:HQY) from Outperform ...
HealthEquity's Q4 revenue beat estimates, but EPS missed. Raymond James upgraded the stock to Strong Buy, citing long-term growth despite fraud concerns.
Raymond James upgraded HealthEquity (HQY) to Strong Buy from Outperform with a price target of $115, down from $120. The firm upgrade the ...
HealthEquity, Inc.’s HQY share price has dipped by 17.07%, which has investors questioning if this is right time to buy.
HealthEquity (NASDAQ:HQY – Get Free Report) was upgraded by analysts at Raymond James from an “outperform” rating to a “strong-buy” rating in a note issued to investors on Tuesday, MarketBeat.com ...
HealthEquity (NASDAQ: HQY) shares have been rather sickly. The health savings account (HSA) specialist's stock was rocked by ...
Shares of HealthEquity, Inc. fell more than 17% on Wednesday, registering the worst drop since December 2021, after the ...
HealthEquity stock drops after mixed Q4 results despite 18.8% revenue growth. Click here to find out why HQY stock is a Hold.
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of HealthEquity, ...
Fintel reports that on March 25, 2025, Raymond James upgraded their outlook for HealthEquity (BMV ... VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,744K shares ...